On August 9, 2023 Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, reported a collaborative initiative focused on increasing access to Cesium-131 brachytherapy for the treatment of certain brain cancers in the form of GT Medical Technologies, Inc.’s ("GT MedTech") GammaTile Therapy (Press release, GT Medical Technologies, AUG 9, 2023, View Source [SID1234634075]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to announce the expansion of our collaboration with GT MedTech to increase our manufacturing in support of their objective of bringing GammaTile Therapy to more patients with difficult to treat brain cancers," said Thijs Spoor, Chief Executive Officer of Perspective. "As the sole producer of Cesium-131 brachytherapy seeds, the therapeutic agent in GammaTile, we value our long-term partnership with GT MedTech and will increase seed production to allow them the capacity to address short notice orders with increased confidence."

GammaTile Therapy is a radiation treatment option implanted during the last five minutes of brain tumor resection surgery. It is composed of bioresorbable collagen tiles embedded with Cesium-131 radiation seeds supplied by Perspective Therapeutics. GammaTile delivers targeted Cesium-131 radiation to help prevent brain tumor cell regrowth in newly diagnosed and recurrent brain tumors, including glioblastomas, metastatic brain tumors, aggressive meningiomas, and other brain tumor types.

Matthew Likens, CEO of GT MedTech, commented, "We are thrilled that Perspective is offering to increase production of Cesium-131 brachytherapy sources for our short notice orders, this will allow us to increase access to GammaTile Therapy, especially in cases where a last-minute opportunity to improve clinical outcomes presents itself. I know our customers will appreciate this increased commitment to patient care."

Perspective Therapeutics is the world’s only producer of Cesium-131 brachytherapy which powers expanded internal radiation treatment options throughout the body, for prostate cancer as well as difficult to treat lung, brain, gynecological, head and neck, pelvic, and colorectal cancers.